What is the mechanism of action of Mobocertinib/Mobocertinib?

Mobocertinib/Mobocertinib(Mobocertinib) is a first-in-class oral tyrosine Kinase inhibitor (TKI) for patients with metastatic non-small cell lung cancer who selectively target epidermal growth factor receptor (EGFR) exon 20 insertion mutation. Mobotinib was approved for marketing in the United States in 20219menstruation and by the China State Food and Drug Administration in 20233menstruation.

Selectively targets wild-typeEGFR EGFRexon20 insertion mutant form and irreversibly inhibits downstream EGFR signaling. About2%of patients with non-small cell lung cancer have EGFR exon 20 insertion mutations. Demonstrated in animals against ASV with EGFRexon20insertNPH (H773_V774insNPH) or ASV Antitumor activity of xenografts (V769_D770insASV). In the primary efficacy study, clinical responses were seen across mutant subtypes (such as NPH, ASV, SVD [D770_N771insSVD]) indicating no correlation between genotype and activity. Common activating mutations(The 19 exon is deleted, the 21exon< /span>858Rreplacement), a drug-resistant mutation that emerged during primary therapyT790M, several rare activating mutations, and human epidermal growth factor receptor(HER) 2and 4, Blymphoid tyrosine kinase(BLK) inhibits EGFR in vitro.

Mobotinib is mainly metabolized by CYP3A and has two active metabolites including AP32960 and AP32914. After oral administration, peak plasma concentrations are reached in approximately 4 hours. The average absolute bioavailability is 37%. Systemic exposure increases in a dose-proportional manner over a dose range of 5 to 180 mg per day. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.